Sino Biopharmaceutical Limited
SBHMYOTCHealthcare● Active
$12.98
$-1.96(-13.12%)
Market Cap$11.6B
P/E Ratio—
52W High$20.16
52W Low$9.48
Sino Biopharmaceutical Limited (SBHMY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SBHMY · earnings · updated Jun 10, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 15, 2025EPS Actual
$0.26
Revenue
$1.23B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 15, 2025
After Market Close
SBHMY reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2026 | Mar 18, 2026 | — | — | — | — | — | — |
| — Q3 FY2025 | Aug 15, 2025 | — | $0.26 | — | $1.23B | — | — |
| ◌ Q2 FY2025 | Jun 5, 2025 | — | — | — | — | — | — |
| — Q1 FY2025 | Mar 26, 2025 | — | $0.00 | — | $0.89B | — | — |
| — Q1 FY2025 | Mar 20, 2025 | — | $0.00 | — | $0.93B | — | — |
| — Q3 FY2024 | Aug 13, 2024 | — | $0.01 | — | $1.09B | — | — |
| — Q2 FY2024 | Apr 8, 2024 | — | $0.01 | — | $1.10B | — | — |
| — Q1 FY2024 | Mar 28, 2024 | — | $0.00 | — | $3.70B | — | — |
Q1 FY2026
Mar 18, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 15, 2025
EPS Actual
$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$1.23B
Q2 FY2025
Jun 5, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 26, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.89B
Q1 FY2025
Mar 20, 2025
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.93B
Q3 FY2024
Aug 13, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.09B
Q2 FY2024
Apr 8, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.10B
Q1 FY2024
Mar 28, 2024
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$3.70B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Aug 15, 2025 | — | $19.50 | $19.50 | +0.00% |
| — Q1 FY2025 | Mar 26, 2025 | — | $8.95 | $8.95 | +0.00% |
| — Q1 FY2025 | Mar 20, 2025 | — | $8.06 | $8.06 | +0.00% |
| — Q3 FY2024 | Aug 13, 2024 | — | $7.25 | $7.25 | +0.00% |
| — Q2 FY2024 | Apr 8, 2024 | — | $7.41 | $7.20 | -2.83% |
| — Q1 FY2024 | Mar 28, 2024 | — | $8.20 | $8.20 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $9.63 | $9.63 | +0.00% |
| — Q1 FY2023 | Mar 31, 2023 | — | $10.82 | $11.18 | +3.33% |
Q3 FY2025+0.00%
Report Date
Aug 15, 2025
EPS Beat/Miss
—
Price Before
$19.50
Price After
$19.50
Q1 FY2025+0.00%
Report Date
Mar 26, 2025
EPS Beat/Miss
—
Price Before
$8.95
Price After
$8.95
Q1 FY2025+0.00%
Report Date
Mar 20, 2025
EPS Beat/Miss
—
Price Before
$8.06
Price After
$8.06
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$7.25
Price After
$7.25
Q2 FY2024-2.83%
Report Date
Apr 8, 2024
EPS Beat/Miss
—
Price Before
$7.41
Price After
$7.20
Q1 FY2024+0.00%
Report Date
Mar 28, 2024
EPS Beat/Miss
—
Price Before
$8.20
Price After
$8.20
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$9.63
Price After
$9.63
Q1 FY2023+3.33%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$10.82
Price After
$11.18
Beat Rate0 / 8 quarters
Largest Move+3.33% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SBHMY ends December
Sino Biopharmaceutical Limited (SBHMY) most recently reported earnings on August 15, 2025 for Q3 FY2025, posting EPS of $0.26 (in line with the analyst consensus of —).
Each quarter, investors track SBHMY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SBHMY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SBHMY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SBHMY earnings · 4 questionsSino Biopharmaceutical Limited's next earnings report is expected around TBD. SBHMY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SBHMY historically reports after market close (AMC).
SBHMY earnings datewhen is SBHMY earningsSBHMY next earnings datewhen does SBHMY report earningsSBHMY earnings calendar
▸ Source: FMP · Sino Biopharmaceutical Limited SEC filings · US GAAP · Sino Biopharmaceutical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026